# Syncom Formulations (India) share price today (Syncom Formulations (India) Ltd, NSE: SYNCOMF)

> Syncom Formulations (India) share price today: ₹20.56 at the NSE close on 4 November 2026, up 27.9% in a year. Syncom Formulations (India) (NSE: SYNCOMF) is worth ₹1,937 crore, trades at a P/E of 22.7 and has closed between ₹10.95 and ₹23.97 over the past 52 weeks. > Syncom Formulations (India) Ltd's earnings have grown faster than its share price. Earnings per share grew +52.8% in a year while the price moved +27.9%. SYNCOMF · Pharma - Others · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/syncom-formulations-indialtd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹20.56 (+27.9% in a year)
- P/E: 22.7× (higher than 53% of the last 11 years)
- Revenue (Jun 2026): ₹126 Cr (+7.7% on a year ago)
- Profit (Jun 2026): ₹25.0 Cr (+56.3% on a year ago)
- Operating margin: 21.0% (+7.0 points on a year ago)
- ROCE: 25%, FY26
- ROIC: 20.2%, against a 12.0% cost of capital: +8.2 points

The main question: profits are rising, but only 50% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Syncom Formulations (India) share price today? Syncom Formulations (India) Ltd's share price was ₹20.56 at the close on 4 November 2026. It has been rising for 9 weeks. That is 21.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹11 and ₹24, and at that close it sat 74% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row. Over the last 11 years the share price moved +764% while the NIFTY 500 moved +257%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Syncom Formulations (India) this quarter? 1. Best operating margin in 15 quarters Operating margin was 21% in the June 2026 quarter, against 14% a year earlier. 2. Profit up on a year earlier for 9 quarters in a row In the June 2026 quarter profit was ₹25 crore, +56.3% on a year earlier. ## What are Syncom Formulations (India)'s latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Syncom Formulations (India) reported revenue of ₹126 crore, up 7.7% from ₹117 crore a year earlier, and a profit of ₹25.0 crore, up 56.3% from ₹16.0 crore. ### Syncom Formulations (India) results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹126 crore | ₹117 crore | +7.7% |
| Profit | ₹25.0 crore | ₹16.0 crore | +56.3% |
| Earnings per share | ₹0.26 | ₹0.17 | +52.9% |
| Operating margin | 21.0% | 14.0% | +7.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Syncom Formulations (India) share price history? Syncom Formulations (India) closed at ₹20.56 on 4 November 2026, up 27.9% from ₹16.07 a year earlier (7 November 2025) and up 99.2% over five years. Its highest weekly close since February 2016 was ₹25.59 on 13 September 2024. ### Syncom Formulations (India) share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹19.25 | +6.8% |
| 1 month ago · 1 Oct 2026 | ₹23.97 | −14.2% |
| 6 months ago · 8 May 2026 | ₹14.71 | +39.8% |
| 1 year ago · 7 Nov 2025 | ₹16.07 | +27.9% |
| 3 years ago · 3 Nov 2023 | ₹8.85 | +132.3% |
| 5 years ago · 4 Nov 2021 | ₹10.32 | +99.2% |
| 10 years ago · 4 Nov 2016 | ₹2.26 | +809.7% |
| Earliest weekly close in our records · 26 Feb 2016 | ₹2.38 | +763.9% |
| Highest weekly close since February 2016 · 13 Sep 2024 | ₹25.59 | −19.7% |
| Lowest weekly close since February 2016 · 13 Mar 2020 | ₹0.56 | +3,571.4% |
| 52-week high (weekly close) · 1 Oct 2026 | ₹23.97 | −14.2% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹10.95 | +87.8% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (567 weekly closes from 26 February 2016 to 4 November 2026.)

## What is the latest news on Syncom Formulations (India)? 4 Nov 2026: Syncom Formulations (India) closed at ₹20.56, up 6.8% on the week and down 14.2% on the month. 23 Sep 2026: ex-date for a dividend of ₹0.10 a share. ### Earlier

- Results for April to June 2026: Revenue up 7.7% and profit up 56.3% on a year earlier. ## What dividend does Syncom Formulations (India) pay? Syncom Formulations (India) paid ₹0.10 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.49% at the ₹20.56 close on 4 November 2026. The last was a dividend of ₹0.10 a share, ex-date 23 September 2026. ### Syncom Formulations (India) dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 23 Sep 2026 | ₹0.10 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Syncom Formulations (India) Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 10 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Syncom Formulations (India) management say on the latest results call? Syncom Formulations (India)'s management made 0 promises we could check against what it later reported. (Our read after the April to June 2026 results, written 10 October 2026.)

## What is the future of Syncom Formulations (India)? What is changing in the business? What is changing at Syncom Formulations (India), from the latest results and calls: operating profitability, lower financing exposure and domestic distribution stocking. - Operating profitability. Operating profit increased faster than sales in the latest quarter. ⚠ estimate
- Lower financing exposure. Reported borrowings have declined. ✓ fact
- Domestic distribution stocking. Management links inventory accumulation to the domestic business. ✓ fact
- Improved operating cash conversion. Latest-year operating cash conversion exceeded the aggregate window. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the April to June 2026 results, written 10 October 2026.)

## What could change the Syncom Formulations (India) story? What are the risks? I would abandon the margin-led progress thesis if the next comparable results showed revenue falling alongside operating profit, while inventory continued accumulating without operating cash conversion. ### Each change stops working if

- Operating profitability: Operating profit declines on comparable sales, indicating that the improved profit per unit of revenue is reversing. - Lower financing exposure: Borrowings rise to fund inventory or distributions while operating cash conversion falls. - Domestic distribution stocking: Inventory grows without subsequent sales and collection improvement. - Improved operating cash conversion: Supplier payment periods shorten before inventory and receivables release cash. ### The main risks

- : Non-operating receipts contribute to reported profit. ⚠ estimate
- : Inventory and supplier financing require follow-through. ⚠ estimate
- : Accounting corrections and limited guidance reduce forecast precision. ⚠ estimate
- : The later outcome of the disclosed review and appeal remains unverified. ⚠ estimate

(Our read after the April to June 2026 results, written 10 October 2026.)

## What to watch in Syncom Formulations (India)'s next results? When Syncom Formulations (India) reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Operating margin declines while sales growth fails to compensate. - What to check ()
- Operating margin declines while sales growth fails to compensate. - Inventory days rise while operating cash conversion falls and payable days shorten. - Further comparative corrections prevent a consistent earnings-per-share bridge. - A subsequent filing recognizes an additional liability or reports an adverse appeal outcome. ## Which stock lists is Syncom Formulations (India) on? Syncom Formulations (India) is on 2 of our India lists: Penny stocks and Pharma stocks. - [Penny stocks Earnings growth, 12 months (%): 46.77](https://www.sectoralpha.in/penny-stocks-india)
- [Pharma stocks Market value (₹ crore): 1933.110187110187](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Syncom Formulations (India) profitable? Syncom Formulations (India) Ltd earned ₹25.0 Cr of net profit in the Jun 2026 quarter, +56.3% on the same quarter a year earlier. That is the 9th quarter in a row of profit growth. Full-year FY26 profit was ₹76.0 Cr. Over 13 years profit has grown 21.6% a year on average. That is 19.8% of the quarter's revenue. The same quarter a year earlier earned ₹16.0 Cr. For the full year, FY26 profit was ₹76.0 Cr (+55.1% on the year before). Why profit moved: revenue changed +7.7% on a year earlier and the margin moved +7.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +49.0% and revenue +1.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Syncom Formulations (India) make, and is it growing? Syncom Formulations (India) Ltd reported ₹126 Cr of revenue in the Jun 2026 quarter, +7.7% on the same quarter a year earlier. Over 13 years it has grown 11.8% a year on average. The last full year, FY26, came in at ₹488 Cr. The last four reported quarters add to ₹498 Cr. FY26 revenue was ₹488 Cr, +5.4% on the year before. Recent pace: the last four quarters grew +1.9% on average, against 11.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +0.4%, against +30.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +48.3%, against +72.2% a year (rolling over). ## How much of every ₹100 of sales does Syncom Formulations (India) keep? Syncom Formulations (India) Ltd's operating margin was 21.0% in the Jun 2026 quarter, 7.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 10 years it has been between 9.0% and 16.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +7.4 percentage points on the year while gross margin changed +6.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Syncom Formulations (India)'s profit turning into cash? Over the last 3 years, 50% of Syncom Formulations (India) Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹58.0 Cr of operating cash against ₹76.0 Cr of profit. After ₹66.0 Cr of spending on assets, free cash was −₹8.0 Cr: it spent more than its operations brought in. Why this happened. This improvement supports a better cash outcome than the earlier negative operating cash period. Longer supplier payment periods also contributed to the shorter cash cycle, so the benefit depends partly on supplier terms. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 50% of profit came in as cash: the cash cycle got 41 days longer between FY17 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 41 days longer. The next section looks at where the cash is stuck. ## Where does Syncom Formulations (India)'s cash go? Syncom Formulations (India) Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 68 days in FY26, up from 27 days in FY17. It spent ₹84.0 Cr on assets over the last 3 years. Customers take 83 days to pay, and stock sits for 81 days on average. At FY26 sales of ₹488 Cr, each day of that cycle ties up about ₹1.3 Cr, so roughly ₹91.0 Cr is tied up in the business at any time. FY26: customers took 83 days to pay and stock sat for 81 days, about 2.7 months of sales sitting as stock, for a full cycle of 68 days, longer than FY17's 27. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 81 days. Customers pay about 83 days after that. Suppliers are paid at 96 days. Together that makes the 68-day cycle. Spending on assets: ₹84.0 Cr over the last 3 years, against ₹17.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Syncom Formulations (India)'s P/E ratio, and how does it compare with its own history? Syncom Formulations (India) Ltd's P/E is 22.7×, in the middle of its own history: higher than 53% of past readings. Its usual P/E (the middle reading) is 20.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +52.8% while the price moved +27.9%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +14.8% a year; about +47.6% a year came from earnings growth and about −32.8 percentage points from the multiple (the market paying less); over 10 years the price moved +24.7% a year; about +21.5% a year came from earnings growth and about +3.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Syncom Formulations (India) share price assume? Worked out from its price on 11 October 2026, Syncom Formulations (India) Ltd's share price assumed profit growth of about 14.6% a year. Over the past 13 years its profit actually grew 21.6% a year. Today its P/E is 22.7×, higher than 53% of its own last 11 years. This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 4 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Syncom Formulations (India) business getting better or worse? Syncom Formulations (India) Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: revenue growth has eased from +70.4% at its peak to +0.4%, but the business is still expanding, with ROCE rising at 28.8%. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## What is the Syncom Formulations (India) story, and has it been checked? Syncom Formulations (India) Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: MID EXPANSION. Our read, 10 October 2026. From the numbers. That label…

From the price. Price stage 2, week 9, above its 200-day line, relative strength falling. From the research. Where they disagree. That label does not rebut the earnings normalization or establish a fresh operating catalyst. What is proven. What is not proven yet. I would abandon the margin-led progress thesis if the next comparable results showed revenue falling alongside operating profit, while inventory continued accumulating without operating cash conversion. What would change our mind. I would abandon the margin-led progress thesis if the next comparable results showed revenue falling alongside operating profit, while inventory continued accumulating without operating cash conversion. The test written in advance. I would abandon the margin-led progress thesis if the next comparable results showed revenue falling alongside operating profit, while inventory continued accumulating without operating cash conversion. Measured by: the thesis as written as stated by the next result. What the surface reading misses. The surface reading is: The latest profit improvement appears to indicate accelerating demand. The research reads it further: Operating profit increased faster than sales, so improved profitability per unit of revenue is the dominant leg. The financial cells do not identify pricing, mix or utilization. What the surface reading misses. The surface reading is: Higher net profit suggests expanding business demand. The research reads it further: Revenue declined while operating profitability improved, and other income also supported reported profit. Sources: our stock research file (10 October 2026) · quarterly results through Jun 2026. The story check is re-scored every results season; the record below never changes. ## How much does Syncom Formulations (India) earn on its capital? Syncom Formulations (India) Ltd earned a ROCE of 25% in FY26. That is up from a low of 10% in FY23. Its return on capital used (ROIC) is 8.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 15.6% net margin and 0.91× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 15.6% net margin × 0.91× asset turnover × 1.29× leverage (assets divided by equity) ≈ 18.3% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 20.2% − 12.0% = +8.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 20.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 19.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Syncom Formulations (India) have too much debt? Syncom Formulations (India) Ltd has total debt of ₹1.0 Cr against shareholder equity of ₹415 Cr as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.26 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Syncom Formulations (India) shareholding pattern? Foreign institutions raised their stake in Syncom Formulations (India) Ltd by 2.1 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.2% of the company. Promoters moved +0.0 points over the same period, to 50.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why the owners changed: foreign institutions drove it (+2.1 points). They raised their stake step by step. ## How far is Syncom Formulations (India) from balance-sheet trouble? For Syncom Formulations (India) Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Syncom Formulations (India) rank in its industry? 71.1 out of 100, rank 1 of 10 in Pharma - Others, with 89% of the evidence available. Syncom Formulations (India) Ltd scores 71.1 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 1. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 20.4 + 17.8 + 15.1 + 17.8 = 71.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Syncom Formulations (India) compared with? Syncom Formulations (India) ranks 1 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 71.1 out of 100. 1. Syncom Formulations (India) Ltd this page SYNCOMF · breaking out · Most evidence points up · 89% evidence 71.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.8/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.8 + 15.1 + 17.8 = 71.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · quiet · Evidence leans up · 78% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.3/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16.3 + 15 + 4.3 = 61.4 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Too little evidence to rank firmly · 48% evidence 59.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 17.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 17.4 + 11.1 = 59.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.5/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.5 + 14.3 = 56.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to Syncom Formulations (India) in size? Syncom Formulations (India) is the 5th largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Unichem Laboratories, Shukra Pharmaceuticals and Panacea Biotec. Just below it: JOJO, TTK Healthcare and Remus Pharmaceuticals. ### Pharma - Others companies close in size

1. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) ₹3,406 crore
2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) ₹3,313 crore
3. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹1,919 crore
4. Syncom Formulations (India) Ltd ₹1,809 crore
5. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,539 crore
6. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,279 crore
7. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) ₹994 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Mold-Tek Packaging Ltd](https://www.sectoralpha.in/stocks/mold-tek-packaging-ltd) ₹1,813 crore · Packaging - FMCG/Consumers
2. [Kross Ltd](https://www.sectoralpha.in/stocks/kross-ltd) ₹1,809 crore · Auto Ancillaries - Transmission
3. Syncom Formulations (India) Ltd ₹1,809 crore
4. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) ₹1,808 crore · Pharma - API & CRAMS
5. [Schneider Electric President Systems Ltd](https://www.sectoralpha.in/stocks/schneider-electric-president-systems-ltd) ₹1,803 crore

## What else do people ask about Syncom Formulations (India)? ### What is Syncom Formulations (India)'s share price today? Syncom Formulations (India) Ltd's share price is ₹20.56, +27.9% over the past year. The whole company is worth ₹1,937 Cr on the market. In the last 52 weeks it traded between ₹11 to ₹24; today it is 74% of the way up from the low, 21.7% above its 200-day average (as of 4 November 2026). ### What were Syncom Formulations (India)'s latest quarterly results? Syncom Formulations (India) Ltd reported revenue of ₹126 Cr and net profit of ₹25.0 Cr for the Jun 2026 quarter. Revenue rose 7.7% and profit rose 56.3% compared with a year earlier. Earnings per share were ₹0.26. The operating margin was 21.0%, 7.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Syncom Formulations (India)'s market cap? Syncom Formulations (India) Ltd's market capitalisation is ₹1,937 Cr at a share price of ₹20.56. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Syncom Formulations (India) performing? Syncom Formulations (India) Ltd's share price has been rising for 9 weeks. In its latest quarter, revenue rose 7.7% and profit rose 56.3% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 14 weeks running (as of 4 November 2026). ### Will Syncom Formulations (India)'s share price go up? This page does not forecast Syncom Formulations (India) Ltd's share price. What it shows instead: the share price is ₹20.56, and it has been rising for 9 weeks. Its P/E of 22.7× is higher than 53% of its own last 11 years (as of 4 November 2026). ### Does Syncom Formulations (India) have too much debt? No, Syncom Formulations (India) Ltd has little debt: its debt is 0.00× its equity, and its operating profit is 77 times its interest bill. FY26 borrowings were ₹1.0 Cr against equity of ₹415 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Syncom Formulations (India) in its business cycle? Syncom Formulations (India) Ltd's FY26 operating margin was 16.0%, against a 10-year range of 9.0% to 16.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 21.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Syncom Formulations (India) story? The main question: profits are rising, but only 50% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Syncom Formulations (India) a stock worth studying right now? What the numbers show: Syncom Formulations (India) Ltd's earnings have grown faster than its share price. Earnings per share grew +52.8% in a year while the price moved +27.9%. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Syncom Formulations (India) share price forecast for 2026? What is changing at Syncom Formulations (India), from the latest results and calls: operating profitability, lower financing exposure and domestic distribution stocking. What would change the story: I would abandon the margin-led progress thesis if the next comparable results showed revenue falling alongside operating profit, while inventory continued accumulating without operating cash conversion. ## Lists

- Penny stocks: https://www.sectoralpha.in/penny-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.